8-Isoprostane in exhaled breath condensate of patients with non-small cell lung cancer: The effect of chemotherapy

Anticancer Research

Volumn 34, Issue 9, 2014, Pages 5143-5145

  Stathopoulos, Dimitrios ^a   Loukides, Stelios ^a   Syrigos, Konstantinos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

8 isoprostane; Chemotherapy; Exhaled breath condensate; Lung cancer

Indexed keywords

8 ISOPROSTANE; 8 EPI PROSTAGLANDIN F2ALPHA; 8-EPI-PROSTAGLANDIN F2ALPHA; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; DRUG DERIVATIVE; PROSTAGLANDIN F2 ALPHA;

ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; ENZYME IMMUNOASSAY; EXHALED BREATH CONDENSATE; FEMALE; HUMAN; INOPERABLE CANCER; LONG TERM SURVIVAL; MALE; NON SMALL CELL LUNG CANCER; OXIDATIVE STRESS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY TRACT PARAMETERS; SENSITIVITY AND SPECIFICITY; TIME TO TREATMENT; TREATMENT RESPONSE; 8-ISOPROSTANE; CHEMOTHERAPY; EXHALATION; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME;

8-ISOPROSTANE; CHEMOTHERAPY; EXHALED BREATH CONDENSATE; LUNG CANCER;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; DINOPROST; EXHALATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; OXIDATIVE STRESS; PROGNOSIS; TREATMENT OUTCOME;

EID: 84908669021     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008. GLOBOCAN 2008. International J Cancer 127: 2893-2917, 2010.
2. Subramaniam S, Thakur RK, Yadav VK, Nanda R, Chowdhury S and Agrawal A: Lung cancer biomarkers: State of the art. Journal of carcinogenesis 12: 3, 2013.
3. Horvath I, Hunt J, Barnes PJ, Alving K, Antczak A, Baraldi E, Becher G, van Beurden WJ, Corradi M, Dekhuijzen R, Dweik RA, Dwyer T, Effros R, Erzurum S, Gaston B, Gessner C, Greening A, Ho LP, Hohlfeld J, Jobsis Q, Laskowski D, Loukides S, Marlin D, Montuschi P, Olin AC, Redington AE, Reinhold P, van Rensen EL, Rubinstein I, Silkoff P, Toren K, Vass G, Vogelberg C, Wirtz H: Exhaled breath condensate: methodological recommendations and unresolved questions. The European respiratory journal 26: 523-548, 2005.
4. Dent AG, Sutedja TG, Zimmerman PV: Exhaled breath analysis for lung cancer. Journal of thoracic disease 5: S540-S550, 2013.
5. Janicka M, Kot-Wasik A, Kot J and Namiesnik J: Isoprostanes-Biomarkers of Lipid Peroxidation: their utility in evaluationg oxidative stress and analysis. International Journal of Molecular Sciences 11: 4631-4659, 2010.
6. Montushi P, Barnes P and Jackson Roberts L: Isoprostanes: markers and mediators of oxidative stress. The FASEB Journal 18: 1791-1800, 2004.
7. Tsim S, O'Dowd CA, Milroy R and Davidson S: Staging of non-small cell lung cancer (NSCLC): a review. Respiratory medicine 104: 1767-1774, 2010.
8. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer 45: 228-247, 2009.
9. Chan H, Tran V, Lewis C and Thomas P: Elevated levels of oxidative stress markers in exhaled breath condensate. Journal of Thoracic Oncology 4: 172-178, 2009.
10. Johns NP and Johns JR: Assessment of 8-isoprostane in urine of non-small cell lung cancer (NSCLC) patients undergoing chemotherapy. Asian Pacific Journal of Cancer Prevention 13: 775-780, 2012.
11. Gupta A, Srivastava S, Prasad R, Natu SM, Mittal B, Negi MP and Srivastava AN: Oxidative stress in non-small cell lung cancer patients after chemotherapy: association with treatment response. Respirology 15: 349-356, 2010.
12. Dalaveris E, Kerenidi T, Katsabeki-Katsafli A, Kiropoulos T, Tanou K, Gourgoulianis KI and Kostikas K: VEGF, TNF-α and 8-isoprostane levels in exhaled breath condensate and serum of patients with lung cancer. Lung cancer 64: 219-225, 2009.
13. Esme H, Cemec M, Sezer M, Saglam H, Demir A, Melek H and Unlu M: High levels of oxidative stress in patients with advanced lung cancer. Respirology 13: 113-116, 2008.
14. Srivastava AN, Gupta A, Srivastava S, Natu SM, Mittal B, Negi MPS and Prasad R: Cisplatin combination chemotherapy induces oxidative stress in advance non-small cell lung cancer patients. Asian Pacific Journal of Cancer Prevention 11: 465-471, 2010.